Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
AFFF Lawsuit Exposure to firefighting foam chemicals may result in an increased risk of cancer for firefighters, military and airport personnel.
Taxotere Hair Loss Claims Must be Reported for Eligibility in Any Future Settlement: Court September 14, 2017 Austin Kirk Add Your Comments The U.S. District Judge presiding over all federal Taxotere hair loss lawsuits is requiring that all claims be identified and reported on a rolling basis, so that they may be eligible for participation in any future settlement program to resolve cases brought by women nationwide. There are currently about 1,500 product liability lawsuits pending against Sanofi-Aventis, over failure to warn women undergoing chemotherapy for breast cancer about the risk that they may be left permanent hair loss due to side effects of Taxotere, which has not been associated with other equally effective treatment options. Given similar questions of fact and law raised in complaints filed throughout the federal court system, the U.S. Judicial Panel on Multidistrict Litigation (JPML) established coordinated pretrial proceedings last year, centralizing all Taxotere claims before U.S. District Judge Kurt Engelhardt in the Eastern District of Louisiana as part of an MDL, or multidistrict litigation. Learn More About Taxotere Lawsuits Side effects of Taxotere may cause sudden eye problems or result in permanent hair loss. Lawsuits reviewed nationwide. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Taxotere Lawsuits Side effects of Taxotere may cause sudden eye problems or result in permanent hair loss. Lawsuits reviewed nationwide. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Although hair loss is a known and accepted part of chemotherapy, women nationwide are pursuing financial compensation due to false and misleading statements made by the makers of Taxotere, which suggested that hair would regrow following treatment, according to the lawsuits. Plaintiffs maintain that if they had been informed about the link between Taxotere and permanent hair loss, they would have elected to receive other breast cancer treatments, which are proven to be equally as effective and do not carry the risk of disfiguring hair problems. As part of the coordinated pretrial proceedings in the Taxotere MDL, Judge Engelhardt has established a “bellwether” process, during which a small group of cases are being prepared for early trial dates to help gauge how juries may respond to certain evidence and testimony that may be repeated throughout the litigation. However, in July, Judge Engelhardt ordered parties involved in the litigation to participate in a Taxotere settlement conference next summer, before the first case is expected to go to trial in September 2018. In a pretrial order (PDF) issued on September 7, all attorneys and law firms participating in the Taxotere MDL were ordered to provide a report to the court on any individuals with potential hair loss claims, even if they are not yet filed in court. The order indicates that identifying and reporting the Taxotere hair loss claims is a requirement for eligibility in any settlement program, calling for initial information to be submitted to the Court by September 30, 2017. However, as additional Taxotere claims are identified, lawyers are required to update their filing, and must ensure that all data and information is current at the end of each quarter. Taxotere Hair Loss Problems Taxotere (docetaxel) is a high potency taxane-based cancer drug, which was introduced by Sanofi-Aventis in 1996 as a superior alternative to existing low-potency taxanes, such as Taxol. However, lawsuits allege that the drug is actually no more effective at treating breast cancer, yet carries a risk of permanent hair loss, or alopecia, which has not been associated with low-potency taxanes. According to allegations raised in Taxotere hair loss claims filed in U.S. District Courts nationwide, Sanofi-Aventis provided false and misleading information for consumers and physicians in the United States, withholding reports of on-going hair problems experienced by users of the high-potency taxane. Plaintiffs maintain that Sanofi-Aventis knew or should have known about the risk of long-term hair loss from Taxotere for years, yet placed their desire for profits before consumer safety. As early as 2005, studies have found that women face a substantial risk of permanent hair loss with Taxotere, including findings that indicate one out of every 10 patients treated with Taxotere suffered hair loss that lasted up to 10 years and five months following chemotherapy, and in some cases longer. While Taxotere warnings in several other countries included information about the permanent alopecia risk, that same information was not provided to American women or doctors. If Taxotere settlements or another resolution for the litigation is not reached following the bellwether trials in the MDL, each individual case pending before Judge Engelhardt may eventually be remanded back to the U.S. District Court where it was originally filed for a separate trial date. Tags: Breast Cancer, Chemotherapy, Hair Loss, Sanofi-Aventis, Taxotere Image Credit: | More Taxotere Lawsuit Stories Taxotere Epiphora Lawsuit Filed Over Excessively Watery Eyes March 24, 2023 Lack of Taxotere Warnings Over Blocked Tear Ducts Justify Lawsuits Moving Forward August 2, 2022 Motion Filed to Dismiss Taxotere Lawsuits Over Excessive Tearing Problems July 7, 2022 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermEmailThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES New Bard Hernia Mesh Lawsuits Continue To Be Filed Following Global Settlement (Posted: today) In the six months since a Bard hernia mesh settlement agreement was reached, at least two dozen new lawsuits have been brought, as the implants continue to fail and require revision surgery. MORE ABOUT: HERNIA MESH LAWSUITHernia Surgery Malpractice Lawsuit Cleared To Move Forward Over Botched Procedure (03/21/2025)Mediation To Discuss Settling Covidien Hernia Mesh Lawsuits Set for March 31 Through April 4 (03/14/2025)Covidien Hernia Mesh Settlement Talks To Get Underway After Parties Select Mediator Next Week (02/19/2025) Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (Posted: yesterday) As new BioZorb lawsuits continue to be filed over complications with the recalled breast tissue markers, lawyers indicate they are on track for the first of four test cases to go before a jury in September 2025. MORE ABOUT: BIOZORB LAWSUITCourt Clears BioZorb Lawsuit Design Defect Claims Over Recalled Breast Tissue Marker (03/26/2025)Group of 7 BioZorb Injury Lawyers Appointed to Leadership Positions in Lawsuits Over Recalled Breast Tissue Marker (03/19/2025)Breast Cancer Survivors File Lawsuit Over Recalled BioZorb Tissue Marker (03/12/2025) Depo-Provera Meningioma Diagnosis Information Required To Qualify for Lawsuit: Order (Posted: 2 days ago) Women pursuing Depo-Provera meningioma lawsuits will have to provide documentary proof of their diagnosis and the versions of the birth control shot they received within 120 days of filing their case. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Lawsuit Timeline for Preparing Pilot Trial Cases Outlined by MDL Judge (03/24/2025)Women Can File Depo-Provera Brain Tumor Lawsuits Directly in MDL: Court Order (03/18/2025)75 Lawyers in Depo-Provera Lawsuits Seek MDL Leadership Roles (03/10/2025)
New Bard Hernia Mesh Lawsuits Continue To Be Filed Following Global Settlement (Posted: today) In the six months since a Bard hernia mesh settlement agreement was reached, at least two dozen new lawsuits have been brought, as the implants continue to fail and require revision surgery. MORE ABOUT: HERNIA MESH LAWSUITHernia Surgery Malpractice Lawsuit Cleared To Move Forward Over Botched Procedure (03/21/2025)Mediation To Discuss Settling Covidien Hernia Mesh Lawsuits Set for March 31 Through April 4 (03/14/2025)Covidien Hernia Mesh Settlement Talks To Get Underway After Parties Select Mediator Next Week (02/19/2025)
Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (Posted: yesterday) As new BioZorb lawsuits continue to be filed over complications with the recalled breast tissue markers, lawyers indicate they are on track for the first of four test cases to go before a jury in September 2025. MORE ABOUT: BIOZORB LAWSUITCourt Clears BioZorb Lawsuit Design Defect Claims Over Recalled Breast Tissue Marker (03/26/2025)Group of 7 BioZorb Injury Lawyers Appointed to Leadership Positions in Lawsuits Over Recalled Breast Tissue Marker (03/19/2025)Breast Cancer Survivors File Lawsuit Over Recalled BioZorb Tissue Marker (03/12/2025)
Depo-Provera Meningioma Diagnosis Information Required To Qualify for Lawsuit: Order (Posted: 2 days ago) Women pursuing Depo-Provera meningioma lawsuits will have to provide documentary proof of their diagnosis and the versions of the birth control shot they received within 120 days of filing their case. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Lawsuit Timeline for Preparing Pilot Trial Cases Outlined by MDL Judge (03/24/2025)Women Can File Depo-Provera Brain Tumor Lawsuits Directly in MDL: Court Order (03/18/2025)75 Lawyers in Depo-Provera Lawsuits Seek MDL Leadership Roles (03/10/2025)